Relevance of Cor Pulmonale in COPD With and Without Pulmonary Hypertension: A Retrospective Cohort Study

Athiththan Yogeswaran1†‡, Stefan Kuhnert1‡, Henning Gall1†, Marlene Faber1, Ekaterina Krauss1, Zvonimir A. Rako1, Stanislav Keranov1, Friedrich Grimminger2†, Hossein Ardeschir Ghofrani1†, Robert Naeije4, Werner Seeger1†, Manuel J. Richter1‡ and Khodr Tello1*†

1 Department of Internal Medicine, Member of the German Center for Lung Research, Universities of Giessen and Marburg Lung Center, Justus-Liebig-University Giessen, Giessen, Germany, 2 Department of Internal Medicine, Member of the German Center for Lung Research, Institute for Lung Health, Cardio-Pulmonary Institute, Universities of Giessen and Marburg Lung Center, Giessen, Germany, 3 Department of Cardiology and Angiology, DZHK (German Center for Cardiovascular Research), University of Giessen, Giessen, Germany, 4 Department of Pathophysiology, Faculty of Medicine, Free University of Brussels, Brussels, Belgium

Background: The relevance of cor pulmonale in COPD and pulmonary hypertension due to COPD (PH-COPD) is incompletely understood. We aimed to investigate the relationship of right ventricular-pulmonary arterial (RV-PA) uncoupling with disease severity in COPD, and the relationship of RV-PA uncoupling and use of targeted PH therapies with mortality in PH-COPD.

Methods: We retrospectively analyzed 231 patients with COPD without PH and 274 patients with PH-COPD. COPD was classified according to GOLD stages and the modified Medical Research Council dyspnoea scale. PH was categorized as mild-to-moderate or severe. RV-PA uncoupling was assessed as the echocardiographic tricuspid annular plane systolic excursion/pulmonary artery systolic pressure (TAPSE/PASP) ratio.

Results: Of the cohort with COPD without PH, 21, 58, 54 and 92 were classified as GOLD I, II, III and IV, respectively. Patients in advanced GOLD stages and those with severe dyspnoea showed significantly decreased TAPSE/PASP. Of the PH-COPD cohort, 144 had mild-to-moderate PH and 130 had severe PH. During follow-up, 126 patients died. In univariate Cox regression, TAPSE/PASP and 6-min walk distance (6MWD; 10 m increments) predicted survival [hazard ratios (95% CI): 0.12 (0.03–0.57) and 0.95 (0.93–0.97), respectively]; notably, PH severity and simplified European Society of Cardiology/European Respiratory Society risk stratification did not. Among patients in the lowest or intermediate tertiles of TAPSE/PASP and 6MWD, those with targeted PH therapy had higher survival than those without (53 vs. 17% at 3 years).

Conclusion: Cor pulmonale (decreased TAPSE/PASP and 6MWD) is associated with disease severity in COPD and predicts outcome in PH-COPD.

Keywords: chronic obstructive pulmonary disease, cor pulmonale, pulmonary arterial hypertension, right ventricle, risk stratification
INTRODUCTION

Pulmonary hypertension (PH) as a complication of COPD is generally mild to moderate but can be severe in some patients (1). Mean pulmonary artery pressures (mPAP) higher than 35–40 mm Hg have been reported in 1–5% of patients with advanced COPD (2–4). PH has long been known to be associated with a reduced life expectancy in COPD, in proportion to increased PAP (5). Early studies also showed that PH due to COPD (PH-COPD) is associated with structural changes in the right ventricle or “cor pulmonale” (6). Altered right ventricular (RV) function was demonstrated by radionuclide angiography and clinicians learned that eventual systemic congestion symptomatology or “pulmonary heart disease” also heralded an increase in mortality in COPD (7–9). More recently, a validated echocardiographic measure of RV-pulmonary arterial (PA) coupling—the tricuspid annular plane systolic excursion (TAPSE)/pulmonary artery systolic pressure (PASP) ratio (10, 11)—was shown to be a strong predictor of outcome in PH on a background of either interstitial lung disease or COPD (12), as well as in heart failure (10, 13) and pulmonary arterial hypertension (PAH) (14). However, the extent to which RV dysfunction explains the altered functional state, decreased exercise capacity and decreased survival of patients with COPD is not exactly known. A risk scoring system for PAH proposed by the European Society of Cardiology and the European Respiratory Society (ESC/ERS) (15) has been successfully transposed to patients with PH due to interstitial lung disease (16) but its utility in patients with PH-COPD remains unknown. Whether targeted PH therapies (which have shown efficacy in PAH) might improve outcome in PH-COPD also remains undecided (1).

We therefore aimed to assess the relationship of disease severity with RV function in patients with COPD without PH, and the relationship of mortality with RV function, PAH-based risk scores and use of targeted PH therapies in patients with PH-COPD.

METHODS

Patients and Study Design

We performed a two-part retrospective cohort study. In the first part, we included 231 patients with COPD without PH who had TAPSE and PASP data available. Echocardiographic and lung function parameters, 6-min walk distance (6MWD), Global Initiative for Obstructive Lung Disease (GOLD) stage, COPD Assessment Test (CAT), and modified Medical Research Council (mMRC) dyspnoea score were evaluated during routine visits to the Department of Pneumology in the Universities of Giessen and Marburg Lung Center. Routine visits took place between 4 August 2010 and 16 July 2021.

In the second part of the study, we included 274 patients with PH-COPD who were enrolled in the Giessen PH registry (17) between August 1995 and December 2018 and who had not previously received targeted PH therapy; some of these patients had also been included in a previously published study (12). Right heart catheterization was performed by experts, with haemodynamic measurements assessed after a short resting period (18). All enrolled patients were followed until June 2020. Survival status was determined by contacting the patient or their physician. Use of PH-specific drugs in severe PH-COPD was decided by experts based on assessment of the individual benefit-risk ratio, as recommended in the current guidelines (15). For patients who were diagnosed with COPD in another centre, the baseline parameters of lung function are missing due to lack of access.

All patients gave written informed consent. The study was approved by the University of Giessen institutional review board (#266/11).

Haemodynamic Classification of PH-COPD

The date of the initial right heart catheterization was taken as the date of PH diagnosis. The final diagnosis was made by a multidisciplinary board including physicians, radiologists and surgeons. PH-COPD was classified as mild-to-moderate or severe according to mPAP and cardiac index as recommended by an expert working group at the 6th World Symposium on PH (1): mPAP between 25 and 34 mm Hg alone or mPAP between 21 and 24 mm Hg with pulmonary vascular resistance (PVR) ≥3 Wood Units was classified as mild-to-moderate PH-COPD, and mPAP ≥35 mm Hg alone or mPAP ≥25 mm Hg with cardiac index <2.0 L/min/m² was classified as severe PH-COPD.

Risk Stratification in PH-COPD

Risk assessment in PH-COPD was performed using a validated simplified version (19) of the ESC/ERS risk stratification system (15). In brief, patients were categorized into low-, intermediate- and high-risk groups based on 6MWD, brain natriuretic peptide (BNP), right atrial pressure (RAP), cardiac index, mixed venous oxygen saturation (SvO₂), right atrial area (echocardiography), World Health Organization functional class and the presence of pericardial effusion (echocardiography), all according to the cut-offs mentioned in the ESC/ERS guidelines (15).

RV-PA coupling was assessed using the TAPSE/PASP ratio determined by echocardiography.

Statistical Analyses

Baseline characteristics are shown as mean ± standard deviation if normally distributed and as median [interquartile range (IQR)] if non-normally distributed. Comparisons between subgroups were performed using either Student’s t-tests or non-parametric tests. Descriptive statistics and correlation analyses were used to evaluate the importance of the TAPSE/PASP ratio in COPD without PH.

In patients with PH-COPD, univariate Cox regression analysis was performed including age, PVR, BNP, 6MWD, SvO₂, RAP, cardiac index, mPAP, right atrial area, the TAPSE/PASP ratio, forced vital capacity (FVC), total lung capacity (TLC), forced expiratory volume in 1 second (FEV₁), the FEV₁/vital capacity (VC) ratio, lung diffusing capacity for carbon monoxide (DLCO), PH-COPD severity (mild-to-moderate or severe), ESC/ERS risk score and body mass index, obstruction, dyspnoea and exercise capacity (BODE) index. TAPSE or PASP alone were not added due to collinearity. All variables that showed a significant association with mortality were included in a
multivariate, stepwise, backward Cox regression model to identify independent predictors of mortality in patients with PH-
COPD. Cut-off values with the highest sensitivity and specificity
for predicting mortality were identified by receiver operating
characteristic analysis and calculation of Youden’s index. No
imputation for missing data was implemented. Survival analyses
were conducted using Kaplan–Meier plots (truncated at 5 years)
and log-rank tests.

All analyses were performed using R 4.0 (the R Foundation,
Vienna, Austria) and SPSS 26.0 (IBM, Armonk, USA).
In the stepwise backward model, parameters with \( p > 0.1 \) were excluded. For all other analyses, \( p < 0.05 \) was
considered significant.

RESULTS

Study Population With COPD

Baseline characteristics of the 231 patients with COPD without
PH are shown in Table 1. The median (IQR) age was 66 (59, 72)
years and 48% of the patients were female. FEV\(_1\)/VC ratio,
FEV\(_1\), TAPSE, mPAP, cardiac index, and DLCO were available in
226 (98%), 226 (98%), 233 (97%), and 223 (97%) patients,
respectively. BNP concentration, 6MWD, CAT score and mMRC
score were available in 209 (90%), 73 (32%), 179 (77%) and 119 (52%) patients, respectively. The TAPSE/PASP ratio did not differ between male and female
patients (\( p = 0.84 \)).

Relevance of TAPSE/PASP in COPD

The TAPSE/PASP ratio differed between GOLD stages I–IV
(ANOVA \( p < 0.001 \)). Patients in higher GOLD stages showed
significantly lower TAPSE/PASP ratios (Table 1). Concordantly,
patients with severe dyspnoea (mMRC grade III or IV) exhibited
a significantly decreased TAPSE/PASP ratio compared with
patients with less severe symptoms [mMRC III/IV: 0.61 (0.50,
0.81) mm/mm Hg; mMRC I/II: 0.75 (0.60, 0.93) mm/mm Hg;
\( p = 0.03 \)], and patients who required oxygen supplementation
showed a lower TAPSE/PASP ratio than those who did not
[0.59 (0.42, 0.74) mm/mm Hg vs. 0.76 (0.62, 0.95) mm/mm
Hg; \( p < 0.001 \)]. Interestingly, patients with exacerbations
leading to inpatient treatment also showed a significantly lower
TAPSE/PASP ratio than those without such exacerbations [0.65
(0.48, 0.77) mm/mm Hg vs. 0.76 (0.60, 0.95) mm/mm Hg;
\( p = 0.001 \)]. Patients with a higher BODE index had a significantly
lower TAPSE/PASP ratio (\( p = 0.034 \); Supplementary Figure 1A).

Correlations of the TAPSE/PASP ratio with different
parameters including lung function are shown in Table 2. The
TAPSE/PASP ratio showed meaningful correlations with age,
6MWD, FEV\(_1\) and DLCO.

Study Population With PH-COPD

Baseline characteristics of the 274 included patients with PH-
COPD are shown in Table 3. The median (IQR) age was 70
(65, 78) years, and most of the patients (62%) were male.
The FEV\(_1\)/VC ratio, FEV\(_1\) and FVC were reduced, PH was on
average mild to moderate and the 6MWD was low. In total,
144 patients (53%) had mild-to-moderate PH-COPD and 130
patients (47%) had severe PH-COPD. Patients with severe PH-
COPD had normal TLC, higher FEV\(_1\)/VC ratios, FEV\(_1\) and FVC
and more severe haemodynamic impairment than patients with
mild-to-moderate PH-COPD (Table 3). The TAPSE/PASP ratio
did not differ between male and female patients (\( p = 0.56 \)),
and was slightly but non-significantly lower in patients with a higher
BODE index (\( p = 0.50 \); Supplementary Figure 1B). Twenty-one
patients were lost to follow-up and were therefore excluded from
survival analysis.

Predictors of Mortality in PH-COPD

During follow-up (truncated at 5 years after diagnosis), 126
patients died. Median survival was 53 months. In univariate
analysis, mPAP, PVR, the TAPSE/PASP ratio, 6MWD, FVC
and the BODE index significantly predicted mortality whereas
age, PH-COPD severity, ESC/ERS risk score, BNP, right
atrial area, SvO\(_2\), RAP, cardiac index, DLCO and other lung
function tests did not (Table 4), although further analysis of
the prognostic capability of DLCO revealed an association
with short-term mortality (truncated at 2 years after diagnosis;
Supplementary Figure 3). The TAPSE/PASP ratio correlated
with mPAP, cardiac index and SvO\(_2\) (Supplementary Table 1).
Only the TAPSE/PASP ratio and 6MWD independently predicted
mortality (Table 4).

Prognostic cut-off values determined by Youden's index were
0.35 mm/mm Hg for the TAPSE/PASP ratio and 299 m for
6MWD. Patients were classified into three risk groups based on
the two predictors: low risk (6MWD and TAPSE/PASP above
the cut-off values), intermediate risk (6MWD or TAPSE/PASP
above the cut-off value), and high risk (neither 6MWD nor
TAPSE/PASP above the cut-off values). As illustrated in Figure 1,
survival at 1, 3 and 5 years was 100, 96, and 87%, respectively,
in the low-risk group, 92, 74, and 62%, respectively, in the
intermediate-risk group, and 75, 46, and 27%, respectively, in
the high-risk group. Cox regression revealed that the risk of mortality
was increased 4-fold in the intermediate-risk group [hazard ratio
(HR): 3.63; 95% CI: 1.05–12.6] and 11-fold in the high-risk group
(HR: 10.5; 95% CI: 3.17–34.9).

Targeted PH therapies were initiated in 57 patients with mild-
to-moderate PH-COPD and 93 patients with severe PH-COPD.
In both groups, survival of patients with targeted PH therapy did
not differ from survival of patients without targeted PH therapy
(Figure 2). We next evaluated survival with vs. without targeted
PH therapy in the three risk groups defined by TAPSE/PASP
and 6MWD. Targeted PH therapies were taken by 10 of 26 patients
at low risk, 32 of 48 patients at intermediate risk, and 41 of
49 patients at high risk. Survival with vs. without targeted PH
therapy showed no significant difference in any of the three risk
groups (Supplementary Figure 4). We also classified the patients
according to TAPSE/PASP tertiles (<0.28 mm/mm Hg, 0.28–
0.41 mm/mm Hg and >0.41 mm/mm Hg) and 6MWD tertiles
(<200, 200–300, and >300 m). In the 63 patients who were in
the lowest or intermediate tertiles of TAPSE/PASP and 6MWD,
those who received targeted PH therapy (\( n = 50 \)) had a higher
survival rate than those without PH therapy (Figure 3; log-rank
\( p = 0.02 \); 3-year survival: 53 and 17%, respectively; HR: 0.36; 95%
CI: 0.14–0.89). Of the patients receiving targeted PH therapy,
## TABLE 1 | Baseline characteristics of patients with COPD without pulmonary hypertension.

| GOLD stage | I (n = 21) | II (n = 58) | III (n = 54) | IV (n = 92) | Unknown (n = 6) |
|------------|------------|------------|------------|------------|---------------|
| Age, years | 61.0 [56.0, 74.0] | 67.0 [60.0, 72.8] | 65.0 [60.0, 71.5] | 66.0 [59.0, 71.0] | 60.5 [51.3, 72.0] |
| n with data | 21 | 58 | 54 | 92 | 6 |
| Male sex, n (%) | 9 (43) | 27 (47) | 32 (59) | 47 (51) | 4 (67) |
| n with data | 21 | 58 | 54 | 92 | 6 |
| Pack years | 40.0 [30.0, 55.0] | 44.5 [30.0, 50.0] | 45.0 [30.0, 60.0] | 40.0 [30.0, 50.0] | 50.0 [35.5, 52.5] |
| n with data | 19 | 52 | 49 | 73 | 3 |
| BMI, kg/m² | 26.4 [22.9, 29.7] | 26.8 [23.5, 30.7] | 26.1 [23.5, 28.9] | 23.2 [20.4, 28.9] | 25.0 [23.1, 26.7] |
| n with data | 20 | 58 | 54 | 92 | 5 |
| FEV₁, % pred | 81.8 [75.6, 87.2] | 60.8 [54.0, 69.1] | 40.4 [34.7, 44.8] | 26.7 [22.6, 32.8] | 61.4 [29.7, 98.5] |
| n with data | 21 | 58 | 52 | 91 | 4 |
| FEV₁/VC max | 66.2 [64.1, 71.0] | 55.7 [47.3, 62.3] | 45.3 [38.2, 49.9] | 36.2 [30.9, 44.9] | 50.0 [33.8, 70.5] |
| n with data | 21 | 58 | 52 | 91 | 4 |
| TLC, % pred | 115 [108, 121] | 114 [100, 123] | 118 [102, 127] | 125 [112, 140] | 114 [103, 124] |
| n with data | 21 | 57 | 51 | 90 | 4 |
| VC, % pred | 98.4 [93.2, 106] | 89.7 [76.2, 99.3] | 72.8 [63.1, 82.0] | 60.0 [49.1, 70.9] | 78.3 [67.2, 99.9] |
| n with data | 21 | 57 | 51 | 90 | 4 |
| FVC, % pred | 90.3 [81.1, 104] | 78.4 [69.9, 91.5] | 61.2 [54.8, 73.7] | 52.0 [43.8, 60.7] | 72.8 [60.0, 97.2] |
| n with data | 20 | 57 | 52 | 90 | 4 |
| DLCO, % pred | 62.7 [50.7, 70.8] | 45.5 [36.7, 69.3] | 36.8 [29.5, 42.6] | 22.4 [17.4, 29.4] | 47.1 [45.2, 59.0] |
| n with data | 20 | 52 | 43 | 46 | 3 |
| TAPSE, mm | 23.0 [21.0, 27.0] | 22.5 [20.0, 25.0] | 22.0 [20.3, 24.8] | 22.0 [19.8, 25.0] | 23.5 [22.0, 25.0] |
| n with data | 21 | 58 | 54 | 92 | 6 |
| PASP, mm/Hg | 24.0 [21.0, 30.0] | 30.0 [25.0, 36.8] | 34.5 [27.0, 39.0] | 35.5 [30.0, 45.0] | 33.5 [28.5, 34.0] |
| n with data | 21 | 58 | 54 | 92 | 6 |
| TAPSE/PASP ratio, mm/mm Hg | 0.90 [0.75, 1.04] | 0.76 [0.59, 0.94] | 0.68 [0.57, 0.82] | 0.60 [0.47, 0.76] | 0.76 [0.68, 0.80] |
| n with data | 21 | 58 | 54 | 92 | 6 |
| BNP, pg/mL | 24.5 [13.8, 28.5] | 30.0 [15.3, 63.8] | 22.0 [12.0, 52.3] | 37.0 [18.0, 73.3] | 24.0 [10.0, 89.0] |
| n with data | 16 | 54 | 52 | 82 | 5 |
| Creatinine, mg/dL | 0.75 [0.70, 1.03] | 0.80 [0.70, 1.00] | 0.80 [0.70, 0.90] | 0.80 [0.63, 1.00] | 0.95 [0.83, 1.08] |
| n with data | 16 | 55 | 54 | 90 | 6 |
| 6MWD, m | 411 ± 145 | 366 ± 140 | 353 ± 91.6 | 257 ± 121 | 269 ± 148 |
| n with data | 5 | 13 | 14 | 39 | 2 |
| mMRC dyspnoea score, n (%) | | | | | |
| 0 | 1 (4.8) | 5 (8.6) | 3 (5.6) | 0 (0) | 1 (17) |
| 1 | 3 (14) | 7 (12) | 5 (9.3) | 2 (2.2) | 0 (0) |
| 2 | 2 (10) | 11 (19) | 6 (11) | 3 (3.3) | 0 (0) |
| 3 | 2 (10) | 11 (19) | 18 (33) | 18 (20) | 0 (0) |
| 4 | 0 (0) | 0 (0) | 5 (3.3) | 16 (17.4) | 0 (0) |
| CAT score | 23.0 [15.5, 25.8] | 22.0 [14.0, 25.0] | 26.5 [19.5, 30.0] | 26.0 [21.8, 30.0] | 13.0 [9.5, 16.5] |
| n with data | 18 | 53 | 46 | 60 | 2 |
| O₂ at rest (L/min) | 3.00 [3.00, 3.00] | 2.00 [2.00, 3.00] | 2.00 [2.00, 2.00] | 2.00 [2.00, 3.00] | 3.00 [3.00, 3.00] |
| n with data | 2 | 12 | 18 | 70 | 1 |
| Long-acting beta-agonist, n (%) | | | | | |
| Unknown | 0 (0) | 1 (1.7) | 4 (7.4) | 4 (4.3) | 3 (50) |
| No | 9 (43) | 10 (17) | 4 (7.4) | 2 (2.2) | 1 (17) |
| Yes | 12 (57) | 47 (81) | 46 (85) | 86 (93) | 2 (33) |
| Long-acting muscarinic antagonist, n (%) | | | | | |
| Unknown | 0 (0) | 2 (3.4) | 4 (7.4) | 4 (4.3) | 3 (50) |
| No | 6 (29) | 10 (17) | 4 (7.4) | 5 (5.4) | 1 (17) |
| Yes | 15 (71) | 46 (79) | 46 (85) | 83 (90) | 2 (33) |

(Continued)
TABLE 1 | Continued

| GOLD stage | I (n = 21) | II (n = 58) | III (n = 54) | IV (n = 92) | Unknown (n = 6) |
|------------|-----------|------------|-------------|------------|----------------|
| Inhaled corticosteroids, n (%) | | | | | |
| Unknown | 0 (0) | 2 (3.4) | 6 (11) | 4 (4.3) | 4 (67) |
| No | 12 (57) | 27 (47) | 10 (19) | 9 (9.8) | 0 (0) |
| Yes | 9 (43) | 29 (50) | 38 (70) | 79 (86) | 2 (33) |
| Theophylline, n (%) | | | | | |
| Unknown | 4 (19) | 7 (12) | 8 (15) | 11 (12) | 3 (50) |
| No | 17 (81) | 49 (84) | 42 (78) | 70 (76) | 3 (50) |
| Yes | 0 (0) | 2 (3.4) | 4 (7.4) | 11 (12) | 0 (0) |
| Roflumilast, n (%) | | | | | |
| Unknown | 5 (24) | 7 (12) | 9 (17) | 13 (14) | 3 (50) |
| No | 16 (76) | 48 (83) | 34 (63) | 62 (67) | 3 (50) |
| Yes | 0 (0) | 1 (1.7) | 10 (19) | 12 (13) | 0 (0) |
| Discontinued | 0 (0) | 2 (3.4) | 1 (1.9) | 5 (5.4) | 0 (0) |

Data are presented as median [interquartile range], mean ± standard deviation or n (%). Numbers of patients with available data are shown in italics. 6MWD, 6-min walk distance; % pred, % predicted; BMI, body mass index; BNP, brain natriuretic peptide; CAT, COPD Assessment Test; DLCO, lung diffusing capacity for carbon monoxide; FEV₁, forced expiratory volume in 1 s; FVC, forced vital capacity; GOLD, Global Initiative for Obstructive Lung Disease; max, maximum; mMRC, modified Medical Research Council; O₂, oxygen; PASP, pulmonary artery systolic pressure; TAPSE, tricuspid annular plane systolic excursion; TLC, total lung capacity; VC, vital capacity. *A total of 103 patients received O₂ supplementation; all other patients did not receive O₂ supplementation.

TABLE 2 | Correlations with the TAPSE/PASP ratio in patients with COPD without pulmonary hypertension.

| Parameter | Pearson R | P-value | Spearman rho | P-value |
|-----------|-----------|---------|--------------|---------|
| Age, years | −0.316 | <0.001 | −0.297 | <0.001 |
| CAT score | −0.141 | 0.06 | −0.133 | 0.08 |
| Pack years | −0.153 | 0.03 | −0.089 | 0.2 |
| 6MWD, m | 0.314 | 0.007 | 0.326 | 0.005 |
| FEV₁, % pred | 0.310 | <0.001 | 0.340 | <0.001 |
| FEV₁/VC max | 0.235 | <0.001 | 0.277 | <0.001 |
| TLC, % pred | −0.123 | 0.07 | −0.092 | 0.2 |
| VC, % pred | 0.281 | <0.001 | 0.274 | <0.001 |
| FVC, % pred | 0.246 | <0.001 | 0.254 | <0.001 |
| DLCO, % pred | 0.423 | <0.001 | 0.414 | <0.001 |

6MWD, 6-min walk distance; % pred, % predicted; CAT, COPD Assessment Test; DLCO, lung diffusing capacity for carbon monoxide; FEV₁, forced expiratory volume in 1 s; FVC, forced vital capacity; max, maximum; PASP, pulmonary artery systolic pressure; TAPSE, tricuspid annular plane systolic excursion; TLC, total lung capacity; VC, vital capacity.

most received monotherapy (94%) with a phosphodiesterase 5 inhibitor (84%) or an endothelin receptor antagonist (16%).

DISCUSSION

The present results show that disease severity in COPD and survival in PH-COPD are predicted by cor pulmonale (assessed as RV-PA uncoupling and decreased exercise capacity) rather than severity of PH or risk scores derived from PAH research. Among patients with low TAPSE/PASP and 6MWD, those who received targeted PH therapies had better survival than those without PH therapies, although statistical significance depended on the TAPSE/PASP and 6MWD thresholds used.

The notion of a right-sided phenotype of heart failure in patients with chronic lung diseases is not new. In 1963, a World Health Organization-sponsored expert consensus conference reviewed chronic lung diseases-associated PH as a cause of heart failure, and defined “cor pulmonale” as RV hypertrophy and dilatation resulting from diseases affecting the structure or function of the lungs (6). This morphological definition proved impractical, and cor pulmonale became better understood as altered RV structure and function with eventual right heart failure symptomatology caused by PH on a background of pulmonary disease, most commonly COPD (7–9). It is interesting that echocardiographic signs of cor pulmonale may be found in patients with COPD and minimally increased PAP, suggesting that factors other than only PH alter RV-PA coupling in COPD (20).
The clinical assessment of cor pulmonale traditionally relied on radionuclide angiography for measurements of RV volumes and derived ejection fraction (EF). This approach established that RVEF is depressed and/or fails to increase during exercise in up to 50% of patients with advanced COPD, and may improve with supplemental oxygen or a variety of pulmonary vasodilating interventions including aminophylline, β2 stimulant drugs or nitrates (8, 9). Radionuclide RVEF was found in one study of 115 patients with COPD to be weakly but significantly correlated to survival (21). Radionuclide angiography has since been replaced by cardiac magnetic resonance imaging (22) or echocardiography.
As recently reviewed, the right ventricle adapts to increased afterload in COPD was assessed by simple 2D echocardiography. With COPD, function as an independent predictor of outcome in patients has been no report of RVEF or any other measure of RV function as an independent predictor of outcome in patients with COPD.

In the present study, coupling of the right ventricle to afterload in COPD was assessed by simple 2D echocardiography. As recently reviewed, the right ventricle adapts to increased afterload by increasing contractility (23, 24). Therefore, correcting contractility (estimated by TAPSE) by an indirect measure of afterload (PASP) provides a more relevant assessment of RV function in patients with various forms of PH (10–14).

The present results confirm the importance of the TAPSE/PASP ratio in COPD both with and without PH. In COPD without PH, the TAPSE/PASP ratio correlated well with specific lung function parameters and 6MWD. Consistent with this finding, patients with a more advanced stage of COPD (mirrored by GOLD stages, mMRC score, need for oxygen supplementation, and presence of exacerbations leading to inpatient treatment) showed significantly reduced RV-PA coupling. In PH-COPD, the TAPSE/PASP ratio was an independent predictor of mortality, whereas the severity of PH alone was not prognostic. This may be a reason why all treatments that aim to decrease PVR or PAP have thus far failed to improve the prognosis of patients with PH-COPD (1).

The most recent proposed classification of severity of PH-COPD from the 6th World Symposium on PH attempts to identify those patients with advanced pulmonary vascular disease who might benefit from the cautious use of targeted therapies, preferably in controlled studies (1). Our patients with moderate or severe PH had a typical profile of high PAP but relatively limited alteration in lung function tests (2–4). It is therefore understandable that targeted PH therapies were prescribed for the treatment of significant pulmonary vascular disease or PAH co-morbidity (1). This strategy was not associated with a detectable effect on outcome when the patient population was analyzed as a whole. However, PH therapy was associated with increased survival in a subgroup analysis of patients in the lowest or intermediate tertiles of both TAPSE/PASP and 6MWD. These results suggest that future trials of targeted PH therapies in PH-COPD should recruit patients with more advanced RV-PA uncoupling, focusing on cor pulmonale rather than the severity of PH per se.

Exercise capacity is markedly reduced in COPD, in proportion to severity of the disease as assessed by the GOLD staging system (25). In a study of 365 patients with COPD, mortality was high (47% during a mean follow-up period of 5.5 years) and was predicted equally well by 6MWD and peak oxygen uptake (26). In another study of 362 patients with COPD who underwent cardiac catheterization and a 6MWD test as part of evaluation for lung transplantation, the prevalence of PH (mPAP > 25 mm Hg and pulmonary arterial occlusion pressure < 16 mm Hg) was 23% and 6MWD declined by 11 m for every 5 mm Hg rise in mPAP, but with borderline significance (p = 0.04) (27). A smaller study of 29 patients with advanced stable COPD showed no significant association between mPAP and exercise capacity (28). Decreased exercise capacity in COPD is mainly related to a ventilatory limitation (26, 28), but analysis of convective and diffusive oxygen transport mechanisms also disclosed a possible influence of cardiac output on skeletal muscle oxygen extraction (29). The present results show the relevance of RV-PA uncoupling in patients with PH-COPD; this could be a possible cause of the cardiac output limitation seen during exercise.

Recent studies have suggested that DLCO is an important predictor of mortality in patients with PH due to chronic lung disease (30, 31). However, univariate Cox regression analysis indicated that DLCO is not associated with 5-year survival in our study cohort. Although the underlying reason for the observed difference cannot be directly assessed in a retrospective cohort analysis, our study supports a role for DLCO as a predictor of short-term mortality.

There are several limitations to the present findings. The study was conducted at a single centre in Germany; the study population may therefore not be representative of the wider population with COPD. The generalizability of the results is also affected by referral bias, as the patients were evaluated at the request of their physicians for a suspicion of PH. Furthermore, only few patients in the high-risk group did not receive targeted PH therapies, and conclusions regarding the efficacy of PH therapies cannot be drawn from...
DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by University of Giessen institutional review board (#266/11), Klinikstraße 29, 35392 Gießen. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

AY, MR, and KT conceived the idea for the analyses detailed in this manuscript. AY undertook statistical analyses of the data in the manuscript. All authors contributed to the design, data collection in the study, drafting and critical review of the manuscript, and approved the manuscript for submission.

FUNDING

This study was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – Projektnummer 268555672 – SFB 1213, Project B08. Editorial assistance was provided by Claire Mulligan, PhD (Beacon Medical Communications Ltd, Brighton, UK), funded by the University of Giessen.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2022.826369/full#supplementary-material
REFERENCES

1. Nathan SD, Barbera JA, Gaine SP, Harari S, Martinez FJ, Olschewski H, et al. Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J. (2019) 53:1801914. doi: 10.1183/13993003.01914-2018

2. Andersen KH, Iversen M, Kjaergaard J, Mortensen J, Nielsen-Kudsk KE, Bendustf E, et al. Prevalence, predictors, and survival in pulmonary hypertension related to end-stage chronic obstructive pulmonary disease. J Heart Lung Transplant. (2012) 31:373–80. doi:10.1016/j.healun.2011.11.020

3. Chauvat A, Bugnet AS, Kadoau N, Schott R, Enache I, Ducolone A, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. (2005) 172:189–94. doi: 10.1164/rcrm.200401-060OC

4. Thabut G, Dauriat G, Stern JB, Levy A, Marrash-Chahla R, et al. Mortality in pulmonary arterial hypertension: validation of the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J. (2017) 50:170074. doi: 10.1183/13993003.00740-2017

5. Fishman AP. State of the art: chronic cor pulmonale. Am Rev Respir Dis. 1988;137:621–6. doi: 10.1163/016344585x12013.

6. Banerjee S, Zielinski B, Krasnowski M, Bhalla K, Banerjee U, et al. Chronic cor pulmonale: survival and treatment strategy. J Thorac Cardiovasc Surg. (2019) 157:1376–83. doi:10.1016/j.jtcvs.2018.10.059

7. Fishman AP. State of the art: chronic cor pulmonale. Am Rev Respir Dis. 1988;137:621–6. doi: 10.1163/016344585x12013.

8. Vogelmeier CF, Kerstjens HAM, Buhl R, Busse R, Calverley PM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Eur Respir J. (2017) 50:649–68. doi: 10.1183/13993003.01993-2016

9. European Respiratory Society (ERS). Pulmonary hypertension in chronic lung disease. Eur Respir J. (2015) 46:903–12. doi: 10.1183/13993003.00329-2015

10. Channick RN, O’Donnell CRJ, Majumdar S, Cabalka A, Badesch DB, et al. American Thoracic Society/European Respiratory Society joint guidelines for the diagnosis and treatment of pulmonary hypertension. Am J Respir Crit Care Med. (2018) 197:1314–34. doi: 10.1164/rccm.201803-0535PP

11. European Respiratory Society (ERS). Pulmonary hypertension in chronic lung disease. Eur Respir J. (2015) 46:903–12. doi: 10.1183/13993003.00329-2015

12. Channick RN, O’Donnell CRJ, Majumdar S, Cabalka A, Badesch DB, et al. American Thoracic Society/European Respiratory Society joint guidelines for the diagnosis and treatment of pulmonary hypertension. Am J Respir Crit Care Med. (2018) 197:1314–34. doi: 10.1164/rccm.201803-0535PP

13. Guazzi M, Bandera F, Pelissero G, Castelvecchio S, Menicanti L, Ghio S, et al. RV contractile function and the coupling to pulmonary circulation in chronic obstructive pulmonary disease. Part two. Am J Respir Crit Care Med. (1994) 150:833–52. doi:10.1164/ajrccm.150.3.8087359

14. Tello K, Axmann J, Ghofrani HA, Weir EK, Misialek JR, et al. Survival in pulmonary hypertension due to chronic lung disease: looking beyond the lungs. J Intern Med. (2020) 287:316–27. doi: 10.1111/1365-2796.13408

15. European Respiratory Society (ERS). Pulmonary hypertension in chronic lung disease. Eur Respir J. (2015) 46:903–12. doi: 10.1183/13993003.00329-2015

16. Channick RN, O’Donnell CRJ, Majumdar S, Cabalka A, Badesch DB, et al. American Thoracic Society/European Respiratory Society joint guidelines for the diagnosis and treatment of pulmonary hypertension. Am J Respir Crit Care Med. (2018) 197:1314–34. doi: 10.1164/rccm.201803-0535PP

17. European Respiratory Society (ERS). Pulmonary hypertension in chronic lung disease. Eur Respir J. (2015) 46:903–12. doi: 10.1183/13993003.00329-2015

18. Vogelmeier CF, Kerstjens HAM, Buhl R, Busse R, Calverley PM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Eur Respir J. (2015) 46:903–12. doi: 10.1183/13993003.00329-2015

19. European Respiratory Society (ERS). Pulmonary hypertension in chronic lung disease. Eur Respir J. (2015) 46:903–12. doi: 10.1183/13993003.00329-2015

Conflict of Interest: AY reports non-financial support from the University of Giessen during the conduct of the study. SK reports personal fees from Chiesi, Berlin Chemie MENARINI and Insmed, and personal fees and non-financial support from GSK, Novartis and AstraZeneca outside the submitted work. HG reports grants from the German Research Foundation and non-financial support from the University of Giessen during the conduct of the study and personal fees from Actelion, AstraZeneca, Bayer, BMS, GSK, Janssen-Cilag, Lilly, MSD, Novartis, OMPT, Pfizer and United Therapeutics outside the submitted work. MF reports non-financial support from the University of Giessen during the conduct of the study. HG reports grants from the German Research
Foundation and nonfinancial support from the University of Giessen during the conduct of the study, and personal fees from Bayer, Actelion, Pfizer, Merck, GSK and Takeda, grants and personal fees from Novartis, Bayer HealthCare and Encysive/Pfizer, and grants from Aires, the German Research Foundation, Excellence Cluster Cardiopulmonary Research and the German Ministry for Education and Research outside the submitted work. RN reports relationships including consultancies, speaker’s fees and membership of advisory boards with AOP Orphan Pharmaceuticals, Johnson & Johnson, Lung Biotechnology Corporation and United Therapeutics. WS reports grants from the German Research Foundation and nonfinancial support from the University of Giessen during the conduct of the study, and personal fees from Pfizer and Bayer Pharma AG outside the submitted work. MR reports grants from the German Research Foundation and non-financial support from the University of Giessen during the conduct of the study, and grants from United Therapeutics, grants and personal fees from Bayer, and personal fees from Actelion, Mundipharma, Roche and OMT outside the submitted work. KT reports grants from the German Research Foundation and non-financial support from the University of Giessen during the conduct of the study, and personal fees from Actelion and Bayer outside the submitted work.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Yogeswaran, Kuhnert, Gall, Faber, Krauss, Rako, Keranov, Grimminger, Ghofrani, Naeije, Seeger, Richter and Tello. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.